Bayer

🧬 Could the future of CRISPR result in a Multi-Billion Dollar Market? Nobel Prize winner Jennifer Doudna thinks it could be! Juergen Eckhardt, Head of Leaps by Bayer recently discussed the transformative potential of #CRISPR technology with Jennifer Doudna, who co-developed this method for gene editing. The CRISPR space is developing at a rapid pace. The first FDA-approved CRISPR therapy for sickle cell disease has rolled out and Doudna remains optimistic about gene editing's future. Key insights from the Magazine Forbes article: - The first CRISPR therapy, approved by the Food and Drug Administration at the end of 2023, can effectively cure a disease that was once untreatable. - Clinical pipelines are advancing rapidly, with Intellia Therapeutics achieving effective in vivo editing with a single injection - CRISPR treatments are showing remarkable results - reducing bad cholesterol by up to 80% in early trials - The biggest technical challenge isn't CRISPR itself but delivery systems for the enzymes Beyond medicine, Doudna is particularly bullish on CRISPR's impact in agriculture, where her team is working on reducing methane emissions from cows and developing drought-resistant rice. But there are obstacles slowing things down. Here’s what is needed next for CRISPR to make an even bigger impact on the world: - Regulatory frameworks that embrace CRISPR as a platform technology - Renewed investor confidence (currently in the "reality check" phase of the biotech hype cycle) - Continued support for basic, curiosity-driven research As Doudna noted, "Innovation comes a lot of times from just studying things that initially don't have a connection to what you want to do, but in the end, you find out they are connected." Eckhardt sees the value in investing in this innovation as well. Leaps by Bayer has invested in companies that use gene editing across health and agriculture, such as Pairwise, eGenesis, Inc. , Capstan Therapeutics, and Metagenom Bio Life Science because their work also aligns with our mission towards #HealthForAll #HungerForNone. What do you think? How can you envision CRISPR transforming agriculture and healthcare in the next decade? Share your thoughts below 👇

Our CEO Bill Anderson shares his reflections on a meeting he attended with Ukrainian President Zelenskyy, which was held at the invitation of German Chancellor Friedrich Merz.

Every mother hopes for a healthy start for her baby, but circumstances and surroundings at birth can greatly affect a child's health and impact their future. Through our Research Initiative for Self-Care Equity (RISE), we uncover the powerful impact of socioeconomic factors on health and identify opportunities for meaningful change for individuals, caregivers, and healthcare professionals. RISE emphasizes the need for personalized self-care solutions, particularly for underserved communities. By recognizing the importance of income and education, we can effectively tackle health issues such as malnutrition, anemia, pain, allergies, and intimate health. Our approach combines research, innovative solutions, policy advocacy, and community engagement to ensure quality healthcare is accessible to everyone. This commitment aligns perfectly with #TeamBayer's mission of #HealthForAll and #HungerForNone, paving the way for improved health outcomes for all, regardless of their socioeconomic background. Together, we can create a lasting impact, empowering people to thrive, raise healthier families, and build better lives. Let’s champion #HealthEquity for a brighter future!

🔭🧪 Ganarle la carrera al dolor, con ciencia e innovación 🧪 🔭 En Bayer, creemos en el poder de la ciencia para mejorar el día a día de las personas. Por eso, desde nuestra división #ConsumerHealth en Argentina, lanzamos una nueva fórmula de Actron Rápida Acción, nuestra marca especializada en el alivio del dolor, con más de 20 años de respaldo en el país. Esta innovación permite aliviar el dolor corporal el doble de rápido, gracias a una cápsula blanda más pequeña y fácil de tomar. Con propiedades analgésicas, antifebriles y antiinflamatorias, ofrece un abordaje completo, ideal para esos momentos en los que el cuerpo necesita volver a sentirse bien. Actron fue el primer ibuprofeno 400 mg en cápsulas blandas en el mercado argentino. Hoy, reafirmamos nuestro compromiso con el bienestar, sumando más rapidez y efectividad, sin perder de vista lo más importante: que cada persona pueda cuidarse de forma segura, accesible y confiable. Porque en Bayer, seguimos innovando para acompañar tu salud con soluciones de calidad. Ciencia para una vida mejor. Autocuidado para todos. Conoce más acá 👉 https://lnkd.in/gaw5hHcV

¿Cómo podemos generar impacto real desde una compañía? En Bayer, creemos que es con acciones que conecten propósito, inclusión y territorio. JUNTAS es una de ellas. Un programa que desarrollamos en alianza con la Universidad Tecnológica Nacional y el #MunicipioDeZárate, que acompaña a mujeres de la comunidad en su formación profesional y su inserción al mundo laboral. 🎓 Formación técnica 💼 Habilidades para la empleabilidad 🤝 Acompañamiento personalizado 🏭 Experiencias en planta 40 mujeres ya están participando de esta edición. Y con ellas, construimos presente y también futuro. #JUNTAS #BayerConoSur #DEI #IndustriaConPropósito #DesarrolloLocal #MujeresEnLaIndustria #Zárate

The latest edition of Nature Magazine, the leading science journal globally, explores advancements in cell therapy, focusing on regenerative treatments for Parkinson's disease by presenting the results from two clinical trials aimed at affirming the safety of such an approach to treat Parkinson’s disease. BlueRock Therapeutics, a clinical-stage cell therapy company and a wholly owned subsidiary of Bayer, has contributed to this edition with an article titled "Phase I trial of hES cell-derived dopaminergic neurons for Parkinson’s disease." Additionally, BlueRock's cover art submission is featured in this edition, highlighting the innovative work being done in this field. Explore the article in Nature: https://lnkd.in/eCzaZgRf Access the full content of the 22 May edition: https://lnkd.in/ed9ecjZA Artwork credit: Nascent Studio

+++ NEWS +++ The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on eye medication with extended treatment intervals. If the European Commission follows the CHMP opinion and grants approval, this will address an important unmet need for patients and physicians in two major retinal diseases: neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME), giving the option to reduce treatment frequency. Once approved, this can mean for patients and their caregivers less injections and clinic visits, opening capacity for ophthalmologists to treat more patients. nAMD and DME are conditions that can severely affect individuals' vision if left untreated, leading to challenges in performing everyday activities and diminishing quality of life. Bayer | Ophthalmology Learn more: https://lnkd.in/e8XtvzUb

“I believe that true fulfillment at work comes from trust and independence. At Bayer, I’m fortunate to work with leaders who support my goals and believe in my abilities. As a Research & Development Specialist at the Ankeny site, my activities include running PCR on DNA samples to validate desired traits. I handle tasks like receiving ordered assays, designing PCR runs, and maintaining our automation systems. I feel proud that my work helps farmers by providing them with reliable agricultural solutions. What excites me most is the diversity at Bayer. Every day, I work with people from different backgrounds who bring fresh perspectives that are essential to brainstorming ideas and solutions. It’s incredible how personal experiences contribute to our collective success.” – Cory Banks How has trust shaped your work experience? Share your thoughts in the comments! #TeamBayer #BayerCareer #BeBayer #ADayInTheLife #WorkLife #BehindTheScenes

Detrás de cada tratamiento, hay algo más que ciencia: hay personas 💚 👩🔬 Investigadores que dedican su vida a buscar y encontrar respuestas. 👨⚕️ Profesionales de la salud que cuidan cada detalle de cada estudio. 🙋♀️ Pacientes que participan con esperanza y la solidaridad de ayudar a otros. 👨👩👧 Familias que acompañan con amor y compromiso. 📍 Todos ellos hacen posible que la innovación en salud avance porque cada nuevo tratamiento innovador está #HechoConCiencia y también con humanidad. #InvestigaciónClínica #Innovación #Ciencia

Over 1.5 billion women suffer from health issues worldwide. We're committed to addressing critical women's health challenges across multiple therapeutic areas: 🫀 Cardiovascular disease is a major burden for women, with stroke associated with a higher mortality rate than a heart attack. Or take heart failure (HF) which affects more than 60 million people worldwide, and approximately half of them suffering from HF with preserved ejection fraction (HFpEF). While the lifetime risk to develop HF is similar in men and women, the prevalence of HFpEF is higher in women than in men and increases with age. We're investing in advancing therapies to address the burden of diseases such as heart failure, chronic kidney disease, stroke, and cardiomyopathies, focusing on areas where the unmet medical need is highest. 👁️ Vision loss impacts 2.2 billion people globally, with women disproportionately affected. Through research and innovation, we're working to reduce vision impairment worldwide. 🎗️ With 2.3 million new breast cancer diagnoses annually, our radiology team drives medical advancements to support early detection, including AI-powered solutions, aiming to improve patient outcomes. 🌟 With 47 million women entering menopause each year, we're committed to supporting women by increasing awareness and broadening therapeutic choices for menopause management. #TeamBayer is dedicated to breaking barriers in pharmaceutical care, because every woman deserves innovative healthcare solutions tailored to her needs.